代謝機能障害関連脂肪性肝炎（MASH）の臨床試験と競合環境が拡大、180社以上が新規治療法を標的に | DelveInsight

The market for Metabolic Dysfunction-Associated Steatohepatitis (MASH) treatments is witnessing significant expansion, with more than 180 companies engaged in research and development. This surge in activity underscores the increasing attention and resources being directed towards finding effective therapies for MASH. The competitive landscape report details over 200 pipeline drugs, encompassing both approved and investigational treatments. It also provides analysis of clinical strategies, upcoming therapeutics, and commercial outlooks. This dynamic environment suggests a robust pipeline and potential for significant advancements in patient care for MASH.